Industry
Biotechnology
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Loading...
Open
0.10
Mkt cap
5.9M
Volume
1.8M
High
0.10
P/E Ratio
N/A
52-wk high
100.50
Low
0.10
Div yield
N/A
52-wk low
0.10
Portfolio Pulse from Benzinga Insights
October 24, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Insights
October 24, 2024 | 12:07 pm
Portfolio Pulse from Avi Kapoor
October 24, 2024 | 10:21 am
Portfolio Pulse from Benzinga Insights
October 23, 2024 | 8:31 pm
Portfolio Pulse from Avi Kapoor
October 23, 2024 | 6:30 pm
Portfolio Pulse from Avi Kapoor
October 23, 2024 | 4:44 pm
Portfolio Pulse from Benzinga Insights
October 23, 2024 | 4:31 pm
Portfolio Pulse from Henry Khederian
October 23, 2024 | 2:08 pm
Portfolio Pulse from Avi Kapoor
October 23, 2024 | 1:50 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 1:15 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.